INDP – indaptus therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Indaptus Therapeutics, Inc. (NASDAQ: INDP) had its price target lowered by analysts at Maxim Group from $8.00 to $5.00. They now have a "buy" rating on the stock.
Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology
Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting
Indaptus Therapeutics to Present at Two Upcoming Investor Conferences
Form 10-Q Indaptus Therapeutics, For: Sep 30
Form 8-K Indaptus Therapeutics, For: Nov 12
Form 8-K Indaptus Therapeutics, For: Oct 17
Form SC 13D Indaptus Therapeutics, Filed by: Meckler Jeffrey A
Form 4 Indaptus Therapeutics, For: Oct 09 Filed by: Waltzman Roger J.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.